NIH National Cancer Institute (NCI)
Administrative Supplements for P30 Cancer Centers Support Grants (CCSG)
Number of supplement applications permitted per institution: 1 supplement request per solicitation per center
Only one supplement application per parent award will be accepted for consideration. For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award.
Supplement solicitations:
- Notice of Special Interest (NOSI): Administrative supplements to understand effects of within-group heterogeneity on cancer control outcomes in underrepresented populations - NOT-CA-24-030
- Notice of Special Interest (NOSI): Administrative supplements to understand effects of within-group heterogeneity on cancer control outcomes in underrepresented populations - NOT-CA-24-032
- Research Supplements to P30 Cancer Center Support Grants (CCSG) and P50 Specialized Programs of Research Excellence (SPORE) Grants to Develop Autologous Human Immune Mouse Models and Organoid Systems for Cancer Immunotherapy Evaluations.
Timeline:
Internal applications due to Stanford Cancer Institute (SCI): April 4, 2024
Candidate Chosen/Notified by SCI: April 10, 2024
For the selected candidates:
Institutional representative (RPM/RMG or CGO/OSR) deadline: April 15, 2024 or April 22, 2024
NCI deadline: April 22, 2024 or April 29, 2024
Program Guidelines:
Applications must be submitted electronically via eRA Commons to the parent award (P30) using PA-20-272 “Administrative Supplements to Existing Grants and Cooperative Agreements (Parent Admin Supplement)” on or before the posted deadline. Submissions should follow the instructions in the Notice of Funding Opportunity (NOFO). See the link to the respective NOSI below or the attached file for details of each solicitation.
Notice of Special Interest (NOSI): Administrative supplements to understand effects of within-group heterogeneity on cancer control outcomes in underrepresented populations - NOT-CA-24-030
Notice of Special Interest (NOSI): Administrative supplements to understand effects of within-group heterogeneity on cancer control outcomes in underrepresented populations - NOT-CA-24-032
Amount of Funding and Research Objectives:
Please see guidelines for details.
Eligibility and Budget Restrictions:
- Only one supplement application per parent award will be accepted for consideration. The supplement proposal will be submitting under the Stanford Cancer Institute’s active P30 award.
- Stanford clarification: The supplement project leader must be faculty with PI eligibility (UTL, UML, NTLR appointments) or CE faculty with an approved CE PI waiver.
Stanford Internal Submission Guidelines:
By April 4, 2024, please submit an internal proposal to the Stanford Cancer Institute HERE. Please upload a single pdf file containing these required documents:
1) Title Page
NCI Administrative Supplements for P30 Cancer Centers Support Grants (CCSG)
Identify the specific solicitation for which you would like to apply (1 – 3 above under Supplement solicitations)
Title of supplement proposal
PI contact information: (name, title, department, address, email)
2) 1 page Research Proposal (figures & references not included in page total)
Font size at least size 11 with half-inch margins (include specific aims, preliminary results, and research design)
3) NIH-format biosketch
Institutional representative: not applicable. You do not need to submit your internal proposal through your institutional official for approval. You may submit your internal proposal directly to SCI via the online submission portal.
Selection Process:
Proposals will be reviewed by a Stanford Cancer Institute review committee. That committee will select the applicants who will represent Stanford
Questions? Please contact Gayle White at gwhite5@stanford.edu or inquiries regarding the internal selection process.
Scientific/Research Contact(s): Please see guidelines for program contacts.
Supplement Notice for Autologous Models